

Appl. No. : 09/931,399
Filed : 08/16/2001

Please cancel Claims 1-12. Please add new claims 39-40. Please amend Claims 13, 24 and 37-38 as follows:

1. (Canceled)
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Canceled)
11. (Canceled)
12. (Canceled)
13. (Currently amended) A method for making a ~~non-liposomal~~ pharmaceutical formulation comprising:
combining a pharmaceutically active agent with a phospholipid to produce a proliposomal combination;
coating said combination with an enteric coating material to produce a coated product, wherein said enteric coating is in contact with at least a portion of said proliposomal combination; and
forming said coated product into a capsule, liquid or suspension.

14. (Original) The method of Claim 13, wherein said pharmaceutically active agent is a poorly water soluble drug.

15. (Original) The method of Claim 13, wherein said pharmaceutically active agent is selected from the group consisting of griseofulvin, famotidine, meclizine, cyclosporine, carbamazepine, methotrexate, itraconazole, dipyridamole, mercaptopurine, halofantrine, amiodarone, lomustine, testosterone, misoprostol, etoposide, rifamycin, azathioprine, glyburide, tolbutamide, aminoglutethimide, taxol, clofibrate, nifedipine, methyldopa, ramipril and dicumarol.

Appl. No. : 09/931,399
Filed : 08/16/2001

16. (Original) The method of Claim 13, wherein said phospholipid is a phosphatidyl phospholipid.

17. (Original) The method of Claim 13, wherein said phospholipid is selected from the group consisting of distearoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, dimyristoyl phosphatidylcholine, egg PC, soy PC, DMPG, DMPA, DPPG, DPPA, DSPG, DSPA, phosphatidylserine and sphingomyelin.

18. (Original) The method of Claim 13, wherein said enteric coating material is selected from the group consisting of cellulose acetate phthalate, alginates, alkali-soluble acrylic resins, hydroxypropyl methylcellulose phthalate, methacrylate-methacrylic acid copolymers, polyvinyl acetate phthalate and styrol maleic acid copolymers.

19. (Original) The method of Claim 13, wherein said coating comprises spraying said combination with said enteric coating material.

20. (Original) The method of Claim 13, further comprising combining at least one additional ingredient which is pharmaceutically inactive with said pharmaceutically active agent.

21. (Original) The method of Claim 20, wherein said at least one additional ingredient is selected from the group consisting of carriers, diluents and lubricants.

22. (Original) The method of Claim 20, wherein said at least one additional ingredient is selected from the group consisting of microcrystalline cellulose, starch, lactose, talc, mannitol, polyethylene glycol, polyvinylpyrrolidone, hydroxypropylmethyl cellulose, ethyl cellulose, fatty acids, fatty acid salts, glyceryl behenate, dextrose and dicalcium phosphate.

23. (Original) The method of Claim 13, wherein said pharmaceutically active agent is selected from the group consisting of anorexics, analgesics, antiarthritics, adrenergic blocking agents, steroids, vaccines, peptides, proteins, hormones, antibodies, antibiotics, antiviral agents, vitamins, nucleotides, nutritional agents, enzymes, genes, genetic material, cytotoxins, bacteria, microbes and viral agents.

24. (Currently amended) A method of making a non-liposomal pharmaceutical formulation comprising:

combining at least one pharmaceutically active agent with at least one phospholipid in a non-aqueous solvent to produce a proliposomal combination;

Appl. No. : 09/931,399
Filed : 08/16/2001

evaporating said non-aqueous solvent; and
applying an enteric coating material to said pharmaceutically active agent and said phospholipid, wherein said enteric coating is in contact with at least a portion of said proliposomal combination.

25. (Original) The method of Claim 24, wherein said pharmaceutically active agent is a poorly water soluble drug.

26. (Original) The method of Claim 24, wherein said pharmaceutically active agent is selected from the group consisting of griseofulvin, famotidine, meclizine, cyclosporine, carbamazepine, methotrexate, itraconazole, dipyridamole, mercaptopurine, halofantrine, amiodarone, lomustine, testosterone, misoprostol, etoposide, rifamycin, azathioprine, glyburide, tolbutamide, aminoglutethimide, taxol, clofibrate, nifedipine, methyldopa, ramipril and dicumarol.

27. (Original) The method of Claim 24, wherein said phospholipid is a phosphatidyl phospholipid.

28. (Original) The method of Claim 24, wherein said phospholipid is selected from the group consisting of distearoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, dimyristoyl phosphatidylcholine, egg PC, soy PC, DMPG, DMPA, DPPG, DPPA, DSPG, DSPA, phosphatidylserine and sphingomyelin.

29. (Original) The method of Claim 24, wherein said enteric coating material is selected from the group consisting of cellulose acetate phthalate, alginates, alkali-soluble acrylic resins, hydroxypropyl methylcellulose phthalate, methacrylate-methacrylic acid copolymers, polyvinyl acetate phthalate and styrol maleic acid copolymers.

30. (Original) The method of Claim 24, wherein said applying an enteric coating material comprises spraying said pharmaceutically active agent and said phospholipid with said enteric coating material.

31. (Original) The method of Claim 24, further comprising combining at least one additional ingredient which is pharmaceutically inactive with said pharmaceutically active agent.

32. (Original) The method of Claim 31, wherein said at least one additional ingredient is selected from the group consisting of carriers, diluents and lubricants.

Appl. No. : 09/931,399
Filed : 08/16/2001

33. (Original) The method of Claim 31, wherein said at least one additional ingredient is selected from the group consisting of microcrystalline cellulose, starch, lactose, talc, mannitol, polyethylene glycol, polyvinylpyrrolidone, hydroxypropylmethyl cellulose, ethyl cellulose, fatty acids, fatty acid salts, glyceryl behenate, dextrose and dicalcium phosphate.

34. (Original) The method of Claim 24, wherein said pharmaceutically active agent is selected from the group consisting of anorexics, analgesics, antiarthritics, adrenergic blocking agents, steroids, vaccines, peptides, proteins, hormones, antibodies, antibiotics, antiviral agents, vitamins, nucleotides, nutritional agents, enzymes, genes, genetic material, cytotoxins, bacteria, microbes and viral agents.

35. (Original) The method of Claim 24, wherein said formulation is in a form selected from the group consisting of capsules; and suspensions-and liquids.

36. (Original) The method of Claim 24, wherein said formulation is in tablet form.

37. (Currently amended) A method for delivering the pharmaceutical formulation of Claim 1 produced by the method of Claim 13 to a mammal comprising orally administering said pharmaceutical formulation to said mammal.

38. (Currently amended) A method for diagnosing, preventing or treating an illness in a mammal comprising administering the pharmaceutical formulation of Claim 1 produced by the method of Claim 13, further comprising providing wherein said pharmaceutical agent is provided in a biologically active dose.

39. (New) The method of Claim 13, wherein said pharmaceutically active agent is a water labile drug.

40. (New) The method of Claim 24, wherein said pharmaceutically active agent is a water labile drug.